Archive for the ‘ Drug Recalls’ Category

« Older Entries

Drug Recalls: Is Avandia Next?

Wednesday, July 28th, 2010

On July 16, 2010, the Food and Drug Administration (FDA) decided to keep the diabetes drug Avandia (rosiglitazone) on the market despite a cardiovascular threat to some patients. Conflicting studies have shown that the drug rosiglitazone promotes increased cardiovascular risk to patients with diabetes.

The FDA, as well as the Endocrine Society, the American Association of Clinical Endocrinologists and the American Diabetes Association, have issued warnings that stopping the drug abruptly may cause a patient more serious short-term health problems and complications.

It is the recommendation of the Southern California drug recall attorneys at the Law Offices of Samer Habbas to speak to your doctor before discontinuing any medication. Oftentimes, people hear reports on the news about defective drugs and suddenly stop taking their medication. The withdrawal effects of abruptly stopping any diabetes medication can result in a rise in blood glucose that can cause complications in the future.

There are alternative medications other than Avandia for diabetes that you can consider if you are at a high risk for cardiovascular episodes. Call your healthcare care provider as soon as possible to determine whether one of these other medications would be right for you.

If you have experienced health problems due to Avandia, you should report them to your doctor right away. You should write down what happened each time and keep the medication bottle. Keeping accurate records of any Avandia drug complications would be crucial if stores pull the product from their shelves.

At The Law Offices of Samer Habbas, we have a team of drug recall attorneys who are here to answer any questions you have. Feel free to call us with questions about the Avandia drug recall at 888.848.5084 or visit our website for up-to-date news on how our civil litigation department is helping clients who have taken defective medication.

Ranbaxy Announces Recall of Antibiotic in U.S.

Tuesday, May 11th, 2010

On the heels of a recall of one lot of their skin care product, pharmaceutical manufacturer Ranbaxy Pharmaceuticals, Inc. has also announced that they are voluntarily recalling two lots of the antibiotic drug from the U.S. market. Drug maker Ranbaxy recently recalled one lot of their 40 milligram Sotret Isotretinoin capsules, a drug that can help acne sufferers have cleaner skin. The company’s second recall involves Lots No 1910779 and 1910782, both with an expiration date of May 2010.

The antibiotic is designed to be mixed with water to form a lotion that can be applied directly to the skin. The company issued the recall after some users complained that when the product was mixed with water, it changed color in ways that previous batches had not. It is unknown if anyone has been injured or disfigured by Sotret Isotretinoin, but anyone with unused product is encouraged to stop using the skin treatment immediately and contact the manufacturer. The FDA is investigating the company for failing to comply with recommended manufacturing practices at two of its plants.

Most pharmaceutical recalls involve drugs that have caused very serious health complications and even death. California pharmaceutical litigation lawyer Samer Habbas knows very well that companies that manufacture products of any kind have a responsibility to ensure that their products are safe to use. As an experienced Los Angeles pharmaceutical litigation lawyer, he has been helping victims and their families recover damages from the manufacturers of defective and dangerous drugs for many years. If you or someone you care for has been injured or lost due to prescription medication, call 888.848.5084 today to speak with Southern California pharmaceutical litigation attorney Samer Habbas and receive answers to your questions.

Resource link: Ranbaxy Announces Recall of Antibiotic in U.S.

FDA Warning Causes Hospira to Issue Recall for the Second Time in Six Months

Wednesday, May 5th, 2010

Drug maker Hospira, Inc. has issued a recall for two of its drugs for the second time in six months due to manufacturing defects. The U.S. Food and Drug Administration recently issued a warning about the defects, prompting the manufacturer to recall Propofol and Liposyn. Propofol, an anesthetic, and Liposyn, an intravenous nutritional product, were recalled April 1. Hospira told the FDA that these two pharmaceuticals had been contaminated with particulates during manufacturing.

The Lake Forest, Illinois based drug maker had previously recalled Propofol and Liposyn in October 2009 due to an equipment failure at one of their plants. The FDA inspected the Clayton, North Carolina manufacturing facility in January and February of this year. The FDA also reviewed the company’s plant in Rocky Mount, North Carolina in January and found a failure to validate processes used for manufacturing undisclosed products.

“We have been working closely with the FDA to find solutions to these problems,” said a Hospira spokesperson who said that the company is conducting “a comprehensive review of its manufacturing operations to ensure compliance with applicable regulations.”

California pharmaceutical litigation lawyer Samer Habbas places an emphasis on client education. To that end, he would like to remind his readers that the manufacturers of any product have a legal obligation to ensure that their products are safe to use. If someone is injured or killed using the product, the manufacturer may be liable for damages. If you or someone you love has been harmed by a defective drug, Southern California pharmaceutical litigation attorney Samer Habbas may be able to help. Mr. Habbas has the experience and resources to handle cases against large pharmaceutical companies and offers free consultations to discuss your case. To schedule your free consultation, call his law offices today at 888.848.5084.

Resource link: Hospira Issues Second Drug Recall in 6 Months on FDA Warning

Drug Company Issues Voluntary Recall of Drug

Tuesday, December 22nd, 2009

Prescription drug manufacturer American Regent has issued a voluntary recall of every lot of their ketorolac tromethamine injection, 30 mg/ml product. The US Food and Drug Administration (FDA) announced recently that particulate matter and crystallization might be present in the drug that could result in obstruction of blood vessels. If a person injects the drug and particulate matter and crystallization is present, it could induce pulmonary emboli or thrombosis or activate platelets and/or neutrophils to induce anaphylactic reactions.

“Other adverse effects associated with the injection of particulate matter include foreign body granulomas, and local irritation at the injection site,” according to an alert sent yesterday from Med Watch, the FDA’s safety information and adverse event reporting program. (more…)

Children’s Tylenol Recalled

Thursday, October 22nd, 2009

This Newsday article claims that the McNeil unit of Johnson & Johnson has voluntarily recalled 57 lots of infants and children’s liquid Tylenol products due to the possibility of bacterial contamination. The Tylenol products manufactured between April and June 2009 included almost two dozen varieties subject to the recall. Johnson & Johnson has said publicly that an inactive ingredient in the various types of product did not meet the company’s internal testing requirements and B. cepacia bacteria was found in a part of the unused material.

The company composed a letter that stated they found no bacteria in the finished product sold to the public, and the possibility of someone becoming seriously ill from contamination of their product was very remote. However, after a consultation with the Food and Drug Administration, the company decided that they would recall the products.

(more…)

« Older Entries